Clinical Trial Update: Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

This update reports the efficacy and safety results from a Phase 2 trial of Zactima (vandetanib) in patients with castration-refractory metastatic prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Zactima (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-07-18